In Brief: CDER reorganization
This article was originally published in The Tan Sheet
CDER reorganization: ODE 5 Director Michael Weintraub will also serve as acting director of FDA Center for Drug Evaluation and Research's new Division of Anti-Inflammatory, Analgesic and Dental Drug Products. Jonathan Wilkin, head of what used to be CDER's Division of Topical Drug Products, becomes director of the Division of Dermatologic and Ophthalmologic Drug Products. FDA previously announced that Debra Bowen, Medical Review Staff director, is acting director of the new Division of OTC Drug Products ("The Tan Sheet" Sept. 18, p. 1). The agency is looking for a replacement for former OTC Medical Officer Man Fung, who left in September. ODE 5 is moving to 9201 Corporate Blvd. in Rockville, Md. before the end of the year...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC